MacuLogix New HQ Announcement
MacuLogix Relocates to Larger Headquarters in Harrisburg, Pennsylvania to Accommodate Rapid Growth
HARRISBURG, PA, February 18, 2019 – MacuLogix®, Inc., the only company to equip eye care professionals with the instrument, tools, and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), relocated its headquarters from Middletown to 3721 TecPort Drive, Ste 301, Harrisburg, PA 17111. The company has grown from 12 to 65 employees in the past three years, including 25 home office employees supporting its national field-based sales and customer success teams.
“The 500% growth of our team is only outpaced by the tremendous growth we’ve seen in sales during the past three years,” said William D. McPhee, President and CEO of MacuLogix. “Designed to reflect our roots as a medical technology start-up, our new headquarters provides a creative and collaborative environment for our team and allows us to showcase our sight-saving device. Plus, we have the option to further expand our footprint as we continue to build the team to meet the growing demand for AdaptDx®.”
“It’s quite humbling and exciting to see the company I co-founded more than a decade ago experience such exponential growth in the past few years,” said Gregory R. Jackson, Ph.D., Chief Technology Officer and Co-founder of MacuLogix. “Since our initial funding was led by Pennsylvania-based Life Sciences Greenhouse of Central Pennsylvania and Ben Franklin Technology Partners, we are very proud to now be officially headquartered in the capital of our home state.”
The new MacuLogix headquarters occupies 17,400 square feet of space on the third floor of an office building it shares with Aetna. Local designer Adrienne Shaver of Studio A Design Group worked closely with the MacuLogix team to design a bright and welcoming environment to accommodate their current and future needs.
MacuLogix, Inc. equips eye care professionals with the instrument, tools, and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor, and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx. Visit www.maculogix.com for additional information.